Skip to main content
Erschienen in: Strahlentherapie und Onkologie 3/2017

03.11.2016 | Review Article

Specific toxicity after stereotactic body radiation therapy to the central chest

A comprehensive review

verfasst von: Feras Oskan, Prof. Dr. med Gerd Becker, Prof. Dr. med Martin Bleif

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

The toxicity of stereotactic body radiation therapy in the central chest remains an unsettled issue. The collected data concerning the observed complications are poorly understood and are limited in their quantity and quality, thus hampering a precise delineation of treatment-specific toxicity. The majority of complications scored as toxicity grade 5, namely respiratory failure and fatal hemoptysis, are most likely related to multiple competing risks and occurred at different dose fractionation schemas, e. g., 10–12 fractions of 4–5 Gy, 5 fractions of 10 Gy, 3 fractions of 20–22 Gy, and 1 fraction of 15–30 Gy. Further investigations with longer follow-up and more details of patients’ pretreatment and tumor characteristics are required. Furthermore, satisfactory documentation of complications and details of dosimetric parameters, as well as limitation of the wide range of possible fractionation schemes is also warranted for a better understanding of the risk factors relevant for macroscopic damage to the serially organized anatomic structure within the central chest.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bezjak A, Paulus R, Gaspar LE et al (2016) Primary study endpoint analysis for NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 94:4–5CrossRef Bezjak A, Paulus R, Gaspar LE et al (2016) Primary study endpoint analysis for NRG Oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 94:4–5CrossRef
2.
Zurück zum Zitat Shanne DH, Nestle U, Allgäuer M et al (2015) Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol 191:125–132CrossRef Shanne DH, Nestle U, Allgäuer M et al (2015) Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol 191:125–132CrossRef
3.
Zurück zum Zitat Kang KH, Okoze CC, Patel RB et al (2015) Complications from stereotactic body radiotherapy for lung cancer. Cancers (Basel) 7:981–1004CrossRef Kang KH, Okoze CC, Patel RB et al (2015) Complications from stereotactic body radiotherapy for lung cancer. Cancers (Basel) 7:981–1004CrossRef
4.
Zurück zum Zitat Evans DJ, Gomez DR, Chang JY et al (2013) Cardiac 18F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol 109:82–88CrossRefPubMed Evans DJ, Gomez DR, Chang JY et al (2013) Cardiac 18F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol 109:82–88CrossRefPubMed
5.
Zurück zum Zitat Timmerman R, Papiez L, McGary R et al (2003) Extracranial stereotactic radioablation: results of phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955CrossRefPubMed Timmerman R, Papiez L, McGary R et al (2003) Extracranial stereotactic radioablation: results of phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955CrossRefPubMed
6.
Zurück zum Zitat McGarry R, Papiez L, Williams M et al (2005) Stereotactic body radiation therapy of early stage lung non-small cell carcinoma: phase I study. J Radiat Oncol Biol Phys 63:1010–1015CrossRef McGarry R, Papiez L, Williams M et al (2005) Stereotactic body radiation therapy of early stage lung non-small cell carcinoma: phase I study. J Radiat Oncol Biol Phys 63:1010–1015CrossRef
7.
Zurück zum Zitat Timmerman R, Lohr F (2005) Normal tissue dose constraints applied in lung stereotactic body radiation therapy. In: Kavanagh BD, Timmerman R (eds) Stereotactic body radiation therapy. Lippincott Williams & Wilkins, Philadelphia, pp 29–37 Timmerman R, Lohr F (2005) Normal tissue dose constraints applied in lung stereotactic body radiation therapy. In: Kavanagh BD, Timmerman R (eds) Stereotactic body radiation therapy. Lippincott Williams & Wilkins, Philadelphia, pp 29–37
8.
Zurück zum Zitat Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early stage lung cancer. J Clin Oncol 24:4833–4839CrossRefPubMed Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early stage lung cancer. J Clin Oncol 24:4833–4839CrossRefPubMed
9.
Zurück zum Zitat Milano MT, Chen Y, Katz AW et al (2009) Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother Oncol 91:301–306CrossRefPubMed Milano MT, Chen Y, Katz AW et al (2009) Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother Oncol 91:301–306CrossRefPubMed
10.
Zurück zum Zitat Baba F, Shibamoto Y, Ogino H et al (2010) Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses dependent on tumor size. Radiat Oncol 5:81CrossRefPubMedPubMedCentral Baba F, Shibamoto Y, Ogino H et al (2010) Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses dependent on tumor size. Radiat Oncol 5:81CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Shibamato Y, Hashizume C, Baba F et al (2012) Stereotactic body radiotherapy using a radiobiolgy-based regimen for stage I non-small cell lung cancer. Cancer 118:2078–2084CrossRef Shibamato Y, Hashizume C, Baba F et al (2012) Stereotactic body radiotherapy using a radiobiolgy-based regimen for stage I non-small cell lung cancer. Cancer 118:2078–2084CrossRef
12.
Zurück zum Zitat Chang JY, Li QQ, Xu QY et al (2014) Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “No Fly Zone”. Int J Radiat Oncol Biol Phys 88:1120–1128CrossRefPubMed Chang JY, Li QQ, Xu QY et al (2014) Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “No Fly Zone”. Int J Radiat Oncol Biol Phys 88:1120–1128CrossRefPubMed
13.
Zurück zum Zitat Modh A, Rimmer A, Williams E et al (2014) Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 90:1168–1176CrossRefPubMedPubMedCentral Modh A, Rimmer A, Williams E et al (2014) Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 90:1168–1176CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Bonomo P, Livi L, Rampini A et al (2013) Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience. Radiol Med 118:1055–1065CrossRefPubMed Bonomo P, Livi L, Rampini A et al (2013) Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience. Radiol Med 118:1055–1065CrossRefPubMed
15.
Zurück zum Zitat Fakiris A, McGarry R, Yinnoutoss C et al (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four years results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75:677–682CrossRef Fakiris A, McGarry R, Yinnoutoss C et al (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four years results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75:677–682CrossRef
16.
Zurück zum Zitat Rowe BP, Boffa DJ, Wilson LD et al (2010) Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol 7:1349–1399 Rowe BP, Boffa DJ, Wilson LD et al (2010) Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol 7:1349–1399
17.
18.
Zurück zum Zitat Stauder MC, McDonald OK, Olivier KR et al (2011) Early pulmonary toicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol 99:166CrossRefPubMed Stauder MC, McDonald OK, Olivier KR et al (2011) Early pulmonary toicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol 99:166CrossRefPubMed
19.
Zurück zum Zitat Tekatli H, Senan S, Dahele M et al (2015) Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes. Radiother Oncol 117:64–70CrossRefPubMed Tekatli H, Senan S, Dahele M et al (2015) Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes. Radiother Oncol 117:64–70CrossRefPubMed
20.
Zurück zum Zitat Joyner M, Salter JB, Papanikolaus N et al (2006) Stereotactic body radiation therpy for centrally located lung lesions. Acta Oncol 45:802–807CrossRefPubMed Joyner M, Salter JB, Papanikolaus N et al (2006) Stereotactic body radiation therpy for centrally located lung lesions. Acta Oncol 45:802–807CrossRefPubMed
21.
Zurück zum Zitat Oskan F, Korhuber C, Krause G et al (2013) Simultaneous stereotactic body radiation therapy of a primary non-small cell lung cancer and synchronous carcinoma in situ in a medically inoperable patient: case report. Radiat Oncol 8:213CrossRefPubMedPubMedCentral Oskan F, Korhuber C, Krause G et al (2013) Simultaneous stereotactic body radiation therapy of a primary non-small cell lung cancer and synchronous carcinoma in situ in a medically inoperable patient: case report. Radiat Oncol 8:213CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Onishi H, Araki T, Shirato H et al (2004) Stereotactic hypofractionated hig-dose irradiation for stage I non-small cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer 101:1623–1631CrossRefPubMed Onishi H, Araki T, Shirato H et al (2004) Stereotactic hypofractionated hig-dose irradiation for stage I non-small cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer 101:1623–1631CrossRefPubMed
23.
Zurück zum Zitat Peulen H, Karlsson K, Lindberg K et al (2011) Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol 101:260–266CrossRefPubMed Peulen H, Karlsson K, Lindberg K et al (2011) Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol 101:260–266CrossRefPubMed
24.
Zurück zum Zitat Song DY, Benedict SH, Cardinale RM et al (2005) Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits. Am J Clin Oncol 28:591–596CrossRefPubMed Song DY, Benedict SH, Cardinale RM et al (2005) Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits. Am J Clin Oncol 28:591–596CrossRefPubMed
25.
Zurück zum Zitat Baumann P, Nyman J, Lax I et al (2006) Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 45:787–795CrossRefPubMed Baumann P, Nyman J, Lax I et al (2006) Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 45:787–795CrossRefPubMed
26.
Zurück zum Zitat Song SY, Choi W, Shin S et al (2009) Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 66:89–93CrossRefPubMed Song SY, Choi W, Shin S et al (2009) Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 66:89–93CrossRefPubMed
27.
Zurück zum Zitat Oshiro Y, Aruga T, Tsuboi K et al (2010) Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol 186:274–279CrossRefPubMed Oshiro Y, Aruga T, Tsuboi K et al (2010) Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol 186:274–279CrossRefPubMed
28.
Zurück zum Zitat Andratschke N, Zimmermann F, Boehm E et al (2011) Stereotactic radiotherapy for of histologically proven inoperable stage I non-small cell cancer: patterns of failure. Radiother Oncol 101:245–249CrossRefPubMed Andratschke N, Zimmermann F, Boehm E et al (2011) Stereotactic radiotherapy for of histologically proven inoperable stage I non-small cell cancer: patterns of failure. Radiother Oncol 101:245–249CrossRefPubMed
29.
Zurück zum Zitat Bral S, Gevarte T, Linthout N et al (2011) Prospective, risk-adapted strategy of stereotactic body radiation therapy for early stage non-small-cell lung cancer: results of phase II study. Int J Radiat Oncol Biol Phys 80:1343–1349CrossRefPubMed Bral S, Gevarte T, Linthout N et al (2011) Prospective, risk-adapted strategy of stereotactic body radiation therapy for early stage non-small-cell lung cancer: results of phase II study. Int J Radiat Oncol Biol Phys 80:1343–1349CrossRefPubMed
30.
Zurück zum Zitat Haasbeek CJ, Laagerwaard FJ, Soltman BJ et al (2011) Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 6:2036–2043CrossRefPubMed Haasbeek CJ, Laagerwaard FJ, Soltman BJ et al (2011) Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 6:2036–2043CrossRefPubMed
31.
Zurück zum Zitat Feddock J, Arnold S, Shelton B et al (2013) Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 85:1325–1331CrossRefPubMed Feddock J, Arnold S, Shelton B et al (2013) Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 85:1325–1331CrossRefPubMed
32.
Zurück zum Zitat Prendergast BM, Dobelbower MC, Bonner JA, Bonner JA et al (2013) Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity resuls using a flattening filter linear accelartor operating at 2400 monitor units per minute. Radiat Oncol 8:273CrossRefPubMedPubMedCentral Prendergast BM, Dobelbower MC, Bonner JA, Bonner JA et al (2013) Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity resuls using a flattening filter linear accelartor operating at 2400 monitor units per minute. Radiat Oncol 8:273CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Karlsson K, Nyman J, Baumann P et al (2013) Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree. Int J Radiat Oncol Biol Phys 87:590–595CrossRefPubMed Karlsson K, Nyman J, Baumann P et al (2013) Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree. Int J Radiat Oncol Biol Phys 87:590–595CrossRefPubMed
34.
Zurück zum Zitat Nishimura S, Takeda A, Sanuki N et al (2014) Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors. J Thorac Oncol 9:1370–1376CrossRefPubMed Nishimura S, Takeda A, Sanuki N et al (2014) Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors. J Thorac Oncol 9:1370–1376CrossRefPubMed
36.
Zurück zum Zitat Han CB, Wang WL, Quint L et al (2014) Pulmonary artery invasion, high-dose radiation, and overall survival in patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 89:313–321CrossRefPubMedPubMedCentral Han CB, Wang WL, Quint L et al (2014) Pulmonary artery invasion, high-dose radiation, and overall survival in patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys 89:313–321CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Feddock J, Cleary R, Arnold S et al (2013) Risk for fatal pulmonary hemorrhage does not appear to be increased following dose escalation using stereotactic body radiotherapy (SBRT) in locally advanced non-small cell lung cancer (NSCLC). J Radiosurg SBRT 2:235–242 Feddock J, Cleary R, Arnold S et al (2013) Risk for fatal pulmonary hemorrhage does not appear to be increased following dose escalation using stereotactic body radiotherapy (SBRT) in locally advanced non-small cell lung cancer (NSCLC). J Radiosurg SBRT 2:235–242
38.
Zurück zum Zitat Chang JY, Xu Q, Balter P et al (2013) Clinical outcome and toxicity in central located or isolated recurrent non-small cell lung cancer treated with stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys 87:514–S515CrossRef Chang JY, Xu Q, Balter P et al (2013) Clinical outcome and toxicity in central located or isolated recurrent non-small cell lung cancer treated with stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys 87:514–S515CrossRef
39.
Zurück zum Zitat Ito M, Niho S, Nihei K et al (2012) Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer 12:27CrossRefPubMedPubMedCentral Ito M, Niho S, Nihei K et al (2012) Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer 12:27CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Kim YH, Kim EY, Ban HY et al (2010) Risk of fatal hemoptysis after concurrent chemoradiation in patients with non-small cell cancer. Chonnam Med J 46:19–24CrossRef Kim YH, Kim EY, Ban HY et al (2010) Risk of fatal hemoptysis after concurrent chemoradiation in patients with non-small cell cancer. Chonnam Med J 46:19–24CrossRef
41.
Zurück zum Zitat Reck M, Barlesi F, Crino L et al (2012) Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC in patients treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 23:1111–1120CrossRefPubMed Reck M, Barlesi F, Crino L et al (2012) Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC in patients treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 23:1111–1120CrossRefPubMed
42.
Zurück zum Zitat Haseltine JM, Rimmner A, Gelblum DY et al (2015) Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol 6(2):e27–e33CrossRefPubMedPubMedCentral Haseltine JM, Rimmner A, Gelblum DY et al (2015) Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol 6(2):e27–e33CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Wulf J, Hadinger U, Oppitz U et al (2001) Stereotactic radiotherapy of targets in the lung and the liver. Strahlenther Onkol 177:645–655CrossRefPubMed Wulf J, Hadinger U, Oppitz U et al (2001) Stereotactic radiotherapy of targets in the lung and the liver. Strahlenther Onkol 177:645–655CrossRefPubMed
44.
Zurück zum Zitat Fink AS, Kim JA, McBride RD (2007) Toxicity and efficacy of treating mediastinal and hilar lesions. In: Urshel HJ (ed) Robotic radiosurgery: treating tumors that move with respiration. Springer, Heidelberg, pp 177–192CrossRef Fink AS, Kim JA, McBride RD (2007) Toxicity and efficacy of treating mediastinal and hilar lesions. In: Urshel HJ (ed) Robotic radiosurgery: treating tumors that move with respiration. Springer, Heidelberg, pp 177–192CrossRef
45.
Zurück zum Zitat Le QT, Loo BW, Ho A et al (2006) Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 1:802–809CrossRefPubMed Le QT, Loo BW, Ho A et al (2006) Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 1:802–809CrossRefPubMed
46.
Zurück zum Zitat Trovo M, Minatel E, Durofil E et al (2014) Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88:114–119CrossRef Trovo M, Minatel E, Durofil E et al (2014) Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys 88:114–119CrossRef
47.
Zurück zum Zitat Kilburn JM, Kuremskz JG, Blackstock AW et al (2014) Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol 110:505–510CrossRefPubMedPubMedCentral Kilburn JM, Kuremskz JG, Blackstock AW et al (2014) Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol 110:505–510CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Park HS, Harder EM, Mancini BR (2015) Central versus peripheral tumor location: influence on survival, local control and toxicity following stereotactic body radiotherapy for primary non-small cell lung cancer. J Thorac Oncol 10:832–837CrossRefPubMed Park HS, Harder EM, Mancini BR (2015) Central versus peripheral tumor location: influence on survival, local control and toxicity following stereotactic body radiotherapy for primary non-small cell lung cancer. J Thorac Oncol 10:832–837CrossRefPubMed
49.
Zurück zum Zitat Corradetti MN, Haas AR, Rengan R (2012) Central-airway necrosis after stereotactic body radiation therapy. N Eng J Med 366:2327–2329CrossRef Corradetti MN, Haas AR, Rengan R (2012) Central-airway necrosis after stereotactic body radiation therapy. N Eng J Med 366:2327–2329CrossRef
50.
Zurück zum Zitat Stephans KL, Djemil T, Diaconu C et al (2014) Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity. Int J Radiat Oncol Biol Phys 90:197–102CrossRefPubMed Stephans KL, Djemil T, Diaconu C et al (2014) Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity. Int J Radiat Oncol Biol Phys 90:197–102CrossRefPubMed
51.
Zurück zum Zitat Dodds WY, Stewart ET, Hodges D et al (1973) Movement of the feline esophagus associated with respiration and peristalsis: an evaluation using tantalum marker. J Clin Invest 52:1–13.CrossRefPubMedPubMedCentral Dodds WY, Stewart ET, Hodges D et al (1973) Movement of the feline esophagus associated with respiration and peristalsis: an evaluation using tantalum marker. J Clin Invest 52:1–13.CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Onimaru R, Shirato H, Schimizu H et al (2003) Tolerance of organs at risk in small volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 56:126–135CrossRefPubMed Onimaru R, Shirato H, Schimizu H et al (2003) Tolerance of organs at risk in small volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 56:126–135CrossRefPubMed
53.
Zurück zum Zitat Guckenberger M, Wulf J, Mueller G et al (2009) Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74:47–54CrossRefPubMed Guckenberger M, Wulf J, Mueller G et al (2009) Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74:47–54CrossRefPubMed
54.
Zurück zum Zitat Kelly P, Balter PA, Rebueno N et al (2010) Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 78:1387–1393CrossRefPubMedPubMedCentral Kelly P, Balter PA, Rebueno N et al (2010) Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 78:1387–1393CrossRefPubMedPubMedCentral
Metadaten
Titel
Specific toxicity after stereotactic body radiation therapy to the central chest
A comprehensive review
verfasst von
Feras Oskan
Prof. Dr. med Gerd Becker
Prof. Dr. med Martin Bleif
Publikationsdatum
03.11.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 3/2017
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-016-1063-z

Weitere Artikel der Ausgabe 3/2017

Strahlentherapie und Onkologie 3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.